Roche (SIX: RO, ROG; OTCQX: RHHBY) announces the completion of the acquisition of LumiraDx’s Point of Care technology, following the receipt of all required antitrust and regulatory clearances. Roche will now embark on the full integration of the company’s innovative multi-assay point of care platform and the related R&D, operational and commercial sites into its global organisation. Through this acquisition, Roche complements its diagnostics portfolio with a simple-to-use platform that consolidates a wide range of immunoassay and clinical chemistry tests on a single instrument, with the future potential to expand into molecular testing.
Read the full article: Roche Closes Acquisition of LumiraDx’s Point of Care Technology to Expand Access to Diagnostic Testing in Primary Care //
Source: https://www.globenewswire.com/news-release/2024/07/29/2920001/0/en/Roche-closes-acquisition-of-LumiraDx-s-Point-of-Care-technology-to-expand-access-to-diagnostic-testing-in-primary-care.html